Cargando…
Acetaminophen pharmacokinetics in infants and children with congenital heart disease
BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current stu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100048/ https://www.ncbi.nlm.nih.gov/pubmed/36264219 http://dx.doi.org/10.1111/pan.14579 |
_version_ | 1785025191994195968 |
---|---|
author | Holladay, Jay Winch, Peter Morse, James Anderson, Brian J. McKee, Christopher T. Rice‐Weimer, Julie Tobias, Joseph D. |
author_facet | Holladay, Jay Winch, Peter Morse, James Anderson, Brian J. McKee, Christopher T. Rice‐Weimer, Julie Tobias, Joseph D. |
author_sort | Holladay, Jay |
collection | PubMed |
description | BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current study prospectively investigated differences in acetaminophen pharmacokinetics following surgery using cardiopulmonary bypass in children with cyanotic and acyanotic congenital heart disease. METHODS: Children (2–6 years, 9–23 kg) presenting for median sternotomy for Fontan palliation (cyanotic patients) or two ventricle surgical repair (acyanotic patients) were eligible for inclusion. A single intravenous dose of acetaminophen (15 mg/kg) was administered at the start of sternal closure after separation from cardiopulmonary bypass. The time‐course of acetaminophen concentrations were described using non‐linear mixed effects models. One and two‐compartment disposition models with first‐order elimination were tested. Pharmacokinetic parameter estimates were scaled using allometry and standardized to a 70 kg person. RESULTS: There were 208 acetaminophen concentrations assayed from 30 children, 15 with cyanotic, and 15 with acyanotic heart disease. A 2‐compartment model best described acetaminophen PK. Parameter estimates (population parameter variability, PPV%; 95% confidence interval, CI) were clearance CL 15.3 L.h‐1.70 kg‐1 (22.2%; 13.8–16.7), intercompartment clearance Q 45.4 L.h‐1.70 kg‐1 (22.4%; 25.2–61.9), central volume of distribution V1 33.5 L.70 kg‐1 (23.2%; 25.9–38.8), peripheral volume of distribution V2 32.1 L.70 kg(−1) (21.7%; 25.9–38.8). Neither clearance nor volume parameters differed between cyanotic and acyanotic patients. CONCLUSIONS: Acetaminophen pharmacokinetics were characterized using a 2‐compartment model with first‐order elimination following cardiac bypass surgery in children. Population pharmacokinetic parameter estimates were similar to other studies in children. No differences were detected between patients with cyanotic and acyanotic heart disease. |
format | Online Article Text |
id | pubmed-10100048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101000482023-04-14 Acetaminophen pharmacokinetics in infants and children with congenital heart disease Holladay, Jay Winch, Peter Morse, James Anderson, Brian J. McKee, Christopher T. Rice‐Weimer, Julie Tobias, Joseph D. Paediatr Anaesth Research Reports BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current study prospectively investigated differences in acetaminophen pharmacokinetics following surgery using cardiopulmonary bypass in children with cyanotic and acyanotic congenital heart disease. METHODS: Children (2–6 years, 9–23 kg) presenting for median sternotomy for Fontan palliation (cyanotic patients) or two ventricle surgical repair (acyanotic patients) were eligible for inclusion. A single intravenous dose of acetaminophen (15 mg/kg) was administered at the start of sternal closure after separation from cardiopulmonary bypass. The time‐course of acetaminophen concentrations were described using non‐linear mixed effects models. One and two‐compartment disposition models with first‐order elimination were tested. Pharmacokinetic parameter estimates were scaled using allometry and standardized to a 70 kg person. RESULTS: There were 208 acetaminophen concentrations assayed from 30 children, 15 with cyanotic, and 15 with acyanotic heart disease. A 2‐compartment model best described acetaminophen PK. Parameter estimates (population parameter variability, PPV%; 95% confidence interval, CI) were clearance CL 15.3 L.h‐1.70 kg‐1 (22.2%; 13.8–16.7), intercompartment clearance Q 45.4 L.h‐1.70 kg‐1 (22.4%; 25.2–61.9), central volume of distribution V1 33.5 L.70 kg‐1 (23.2%; 25.9–38.8), peripheral volume of distribution V2 32.1 L.70 kg(−1) (21.7%; 25.9–38.8). Neither clearance nor volume parameters differed between cyanotic and acyanotic patients. CONCLUSIONS: Acetaminophen pharmacokinetics were characterized using a 2‐compartment model with first‐order elimination following cardiac bypass surgery in children. Population pharmacokinetic parameter estimates were similar to other studies in children. No differences were detected between patients with cyanotic and acyanotic heart disease. John Wiley and Sons Inc. 2022-11-07 2023-01 /pmc/articles/PMC10100048/ /pubmed/36264219 http://dx.doi.org/10.1111/pan.14579 Text en © 2022 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Reports Holladay, Jay Winch, Peter Morse, James Anderson, Brian J. McKee, Christopher T. Rice‐Weimer, Julie Tobias, Joseph D. Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title | Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title_full | Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title_fullStr | Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title_full_unstemmed | Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title_short | Acetaminophen pharmacokinetics in infants and children with congenital heart disease |
title_sort | acetaminophen pharmacokinetics in infants and children with congenital heart disease |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100048/ https://www.ncbi.nlm.nih.gov/pubmed/36264219 http://dx.doi.org/10.1111/pan.14579 |
work_keys_str_mv | AT holladayjay acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT winchpeter acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT morsejames acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT andersonbrianj acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT mckeechristophert acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT riceweimerjulie acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease AT tobiasjosephd acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease |